FindTrial
Sign In

Canceled by the investigator. Clinical study of combined action of the first generation of TKIs and brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis

Clinical study of combined action of the first generation of TKIs and brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012098
Enrollment
Unknown
Registered
2017-07-23
Start date
2017-06-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

TKIs group:first generation of TKIs
TKIs and brain radiotherapy:TKIs and brain radiotherapy

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patient confirmed NSCLS; 2.MRI indicated that the measurable brain metastasis lesion; 3.Patient with EGFR mutations; 4.Aged 18 ~ 75 years old; ECOG PS 0 ~ 2 points;Life expectancy > 3 months; 5.All subjects or their guardians must sign the subject informed consent before entering the test.

Exclusion criteria

Exclusion criteria: 1. Intracranial pressure causes vomiting; 2. Severe liver, kidney and lung injury; 3. Allergic to the first generation of TKIs; 4. Only with meningeal metastases.

Design outcomes

Primary

MeasureTime frame
intracranial Progression free survival;systemic Progression free survival;Overall survival;—

Countries

China

Contacts

Public ContactYu Li

The Second Hospital of ShanDong University

qlliyu@163.com+86 18560082770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026